Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Covalent Modifiers

JULY 25, 2024

We have integrated structural and quantitative proteomics with biochemical assays to decipher the mode of action of covalent USP30 inhibition by a small molecule containing a cyanopyrrolidine reactive group, USP30-I-1.

Biochemical Assays 182

Biochemical Assays Small Molecule Treatment Disease 182

ASPET

DECEMBER 21, 2023

Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemical assays.

Biochemical Assays 100

Biochemical Assays Small Molecule Disease Regulations 100

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We often screen using a biochemical assay, but we can conduct cell-based screening as well. We need to build the assays that we need for compound screening.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Molecular Design

JULY 18, 2020

While I’m not particularly keen on the use of the term ‘open source’ in this context, I have absolutely no quibble with the goal of seeking cures and treatments for diseases that are ignored by commercial drug discovery organizations.

Biochemical Assays 52

Biochemical Assays Fragment Screening Pharmacokinetics Drugs 52

Sygnature Discovery

MARCH 14, 2025

Advanced Automation in Sygnature Discoverys HTS System Our high throughput screening system, developed by HighRes Biosolutions, is designed for versatility, accommodating both cell and biochemical assays. Central to our automation is the Echo acoustic dispensing technology, ensuring highly accurate compound delivery.

52

52

Agency IQ

JUNE 26, 2023

This includes treatments or therapeutics that are intended to serve a specific population that can only be selected (or excluded) via diagnostic guidelines, products for which a diagnostic could identify high-risk patients, and/or those that require monitoring for treatment adjustments. For now, LDTs are filling the gap.

FDA 40

FDA Clinical Trials Laboratories Science 40